AMSTERDAM, The Netherlands, May 15, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, today announced that the Board of Directors of Eurand N.V. will convene an Annual General Meeting ("AGM") of the Company's shareholders on Friday, May 30, 2008 at 10:00AM (CET). The meeting will be held at Eurand's offices in Amsterdam, The Netherlands located at Fred Roeskestraat 123, 1076 EE Amsterdam, The Netherlands.
Proxy materials have been distributed to shareholders of record and have been made available on the Company's website in compliance with the Dutch Corporate Governance Code and in hard copy upon request from the Company's registered office. Shareholders registered as at the record date of May 5, 2008, are eligible to participate in the meeting. Details about how to register for the meeting are included in the convening notice that can be found on the Company's website, together with the proxy materials at: http://ir.eurand.com/meetings.cfm
About Eurand
Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four partnered products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand has completed two phase III clinical trials on its lead product candidate, EUR-1008 (Zentase), intended for the treatment of Exocrine Pancreatic Insufficiency and has submitted an NDA for this product which has been granted priority review. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs, customized release, taste-masking/fast-dissolving formulations and drug conjugation.
Eurand is a global company with facilities in the USA and Europe. For more information, visit Eurand's website at www.eurand.com.
This release, and oral statements made with respect to information contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to the status of our NDA filing and the plans for MAA filing relating to EUR-1008, enrollment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words "potentially", "could", "calls for" and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the FDA does not approve our NDA or delays approval; the outcome of any discussions with the FDA; and unexpected delays in preparation of materials for submission to the FDA as a part of our NDA filing. Forward-looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward-looking statements.